Expertise in
52
conditions

Dr. Jonathan Whisenant

Oncology
5131 S Cottonwood St Ste L-2, 
Murray, UT 
On Staff At
Accepting New Patients
Offers Telehealth
Referral may be required
Expertise in
52
conditions
5131 S Cottonwood St Ste L-2, 
Murray, UT 

Overview

Jonathan Whisenant is an Oncologist practicing medicine in Murray, Utah.

Dr. Whisenant is highly rated in 52 conditions, according to our data. His clinical expertise encompasses Cholangiocarcinoma (Bile Duct Cancer), Gastrointestinal Stromal Tumor, Colorectal Cancer, and Familial Colorectal Cancer.

Dr. Whisenant is board certified in American Board Of Internal Medicine. He is actively involved in clinical research, co-authoring 20 peer reviewed articles and participating in 11 clinical trials. Dr. Whisenant is currently accepting new patients.

Graduate Institution

University Of California San Francisco

Residency

University of Colorado Hospital

Specialties

Oncology

Licenses

Internal Medicine in UT

Board Certifications

American Board Of Internal Medicine

Fellowships

Univ of CA San Francisco

Hospital Affiliations

Riverton Hospital
St Mark's Hospital
Intermountain Medical Center
Lds Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
BridgeSpan
  • EPO
  • HMO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Deseret Mutual Benefit Administrators
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Regence
  • EPO
  • PPO
SelectHealth
  • HMO
  • POS
Steward Health Care
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
University of Utah Health
  • EPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Utah Cancer Specialists
5131 S Cottonwood St Ste L-2, Murray, UT 84107
Other Locations
Utah Cancer Specialists
389 S 900 E Ste 100, Salt Lake City, UT 84102
Utah Cancer Specialists
3838 S 700 E Ste 100, Salt Lake City, UT 84106
Ldsh Shared Physician Services
8 Th Avenue C St, Salt Lake City, UT 84143

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: April 14, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
Enrollment Status: Completed
Publish Date: February 10, 2026
Intervention Type: Device, Biological, Other, Drug
Study Drugs: Cetuximab, Irinotecan, Pertuzumab, Trastuzumab
Study Phase: Phase 2
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Other, Drug
Study Drug: Trametinib
Study Phase: Phase 2
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid Tumors
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid Tumors
Enrollment Status: Completed
Publish Date: August 01, 2023
Intervention Type: Biological
Study Drug: Enapotamab vedotin 
Study Phase: Phase 1/Phase 2
Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With LCL161, Everolimus (RAD001) or Panobinostat (LBH589)
Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With LCL161, Everolimus (RAD001) or Panobinostat (LBH589)
Enrollment Status: Completed
Publish Date: January 11, 2023
Intervention Type: Drug, Biological
Study Drugs: PDR001, LCL161, Everolimus, Panobinostat, QBM076, HDM201
Study Phase: Phase 1
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Enrollment Status: Completed
Publish Date: October 06, 2022
Intervention Type: Drug
Study Drugs: Avapritinib, Regorafenib
Study Phase: Phase 3
An Observational Study to Collect and Assess Tissue Samples From Subjects With One of Three Neoplastic Conditions (ANSWer)
An Observational Study to Collect and Assess Tissue Samples From Subjects With One of Three Neoplastic Conditions (ANSWer)
Enrollment Status: Completed
Publish Date: April 05, 2022
Intervention Type: Other
Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma
Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma
Enrollment Status: Terminated
Publish Date: June 22, 2021
Intervention Type: Drug
Study Phase: Phase 2
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: October 19, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

20 Total Publications

Author Correction: Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers.
Author Correction: Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers.
Journal: Nature medicine
Published: April 25, 2025
Similar Doctors
Expertise in
17
conditions
Dr. Neeraj Agarwal
Oncology
Expertise in
17
conditions
Dr. Neeraj Agarwal
Oncology

Huntsman Cancer Institute, Hematology-Oncology

1950 Circle Of Hope Dr, 
Salt Lake City, UT 
 (8.2 miles away)
801-585-0100
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Neeraj Agarwal is an Oncologist practicing medicine in Salt Lake City, Utah. Dr. Agarwal is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Orchiectomy, and Tissue Biopsy. Dr. Agarwal is board certified in American Board Of Internal Medicine. Dr. Agarwal is currently accepting new patients.

Expertise in
17
conditions
Dr. Ignacio Garrido
Oncology
Expertise in
17
conditions
Dr. Ignacio Garrido
Oncology

Hematology-Oncology - Nielsen Rehabilitation Hospital

85 N Medical Dr, 
Salt Lake City, UT 
 (8.1 miles away)
801-585-0100
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ignacio Garrido is an Oncologist practicing medicine in Salt Lake City, Utah. Dr. Garrido is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatoblastoma, and Pancreatectomy. Dr. Garrido is board certified in American Board Of Internal Medicine. Dr. Garrido is currently accepting new patients.

Expertise in
16
conditions
Dr. Michael Pulsipher
Hematology | Oncology
Expertise in
16
conditions
Dr. Michael Pulsipher
Hematology | Oncology

Pediatric Bone Marrow Transplant

100 N Mario Capecchi Dr, 
Salt Lake City, UT 
 (8.0 miles away)
801-662-4700
Languages Spoken:
English
See accepted insurances

Michael Pulsipher is a Hematologist and an Oncologist practicing medicine in Salt Lake City, Utah. Dr. Pulsipher is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Graft Versus Host Disease (GvHD), Leukemia, Severe Combined Immunodeficiency (SCID), and Bone Marrow Transplant. Dr. Pulsipher is board certified in American Board Of Pediatrics.

Frequently Asked Questions about Dr. Jonathan Whisenant

How do I make an appointment with Dr. Jonathan Whisenant?

You can book an appointment with Dr. Jonathan Whisenant by calling their office at 801-263-3416. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jonathan Whisenant a top-rated expert for Cholangiocarcinoma (Bile Duct Cancer)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jonathan Whisenant is classified as an Distinguished expert for Cholangiocarcinoma (Bile Duct Cancer), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jonathan Whisenant specialize in?

While Dr. Jonathan Whisenant is a Oncology, they have specific expertise in Cholangiocarcinoma (Bile Duct Cancer), Gastrointestinal Stromal Tumor, and Colorectal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Jonathan Whisenant participate in research or clinical trials?

Yes. Dr. Jonathan Whisenant has published 20 articles and abstracts on conditions like Cholangiocarcinoma (Bile Duct Cancer). You can view a list of Dr. Jonathan Whisenant's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jonathan Whisenant accept my insurance?

Dr. Jonathan Whisenant accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 801-263-3416 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Whisenant's expertise for a condition
ConditionClose
    View All 47 Advanced Conditions
    View All 145 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile